Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods

Abstract

Clinical mass spectrometry proteomics (cMSP) assays are being increasingly used in clinical laboratories for analyzing peptides and proteins. It has therefore become urgent to characterize and validate the methods available for liquid chromatography–tandem mass spectrometry (LC/MS–MS) targeted quantification of peptide and protein biomarkers in biological fluids in the context of in vitro diagnostics. LC–MS/MS for the detection of peptides and proteins is currently the main approach used in the field of cMSP. As a result of their selectivity, low reagent costs and the fact that these methods can be used for absolute quantification and multiplexing, they will likely eventually replace immunoassays. Although LC–MS/MS is known to be the main reference method involved in reference measurement procedures (RMPs), it needs to meet the requirements of in vitro diagnostic (IVD) regulations and standards. This review shows that cMSP is fully compatible with the regulatory IVD requirements and provides an overview of the characterization and validation of the use of LC–MS/MS targeted quantification of clinical protein biomarkers in biological fluids.

Keywords:

• Clinical mass spectrometry
• guidelines
• LC–MS
• method validation

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) through the activity of the Clinical Quantitative Mass Spectrometry Proteomics Working Group (WG-cMSP).